Abstract:ID 93958 Poster Board 481 A 3 adenosine receptor (AR) agonists are being developed for the treatment of autoimmune inflammatory diseases, chronic pain and cancer. A 3 AR agonists are not limited by cardiovascular side effects observed with other adenosine (A 1 and A 2A ) agonists that were in clinical trials. 2-Arylethynyl (North)-methanocarba adenosines have been explored as highly selective A 3 AR agonists, which is largely a function of the pseudoribose (bicyclic fused cyclopropane and cyclopentane) ring that pre-establishes a preferred (N) conformation for receptor recognition. Here, we compare analogues in the 5¢methylamide series having bulky C2-substitution, which either contain or lack an ethynyl spacer between adenine and a cyclic group. 2-Aryl compounds 11 , 13 , 14 , 19 , 22 , 23 , 27 , 29 , 31 and 34 , lacking an ethynyl spacer, displayed potent K i values of 2–30 nM at the human (h) A 3 AR, while other derivatives had greatly reduced affinity. The mouse (m) A 3 AR affinity was highly variable, with 2-arylethynyl groups greatly favoring high affinity ( 7 , 8 > 3c , 3d > 3b ) compared to 2-aryl analogues. However, 4¢truncated derivatives lacking a 2-ethynyl spacer had greatly reduced hA 3 AR affinity, even for those analogues containing affinity-enhancing N 6 -dopamine-derived substituents. This suggests that the 5¢methylamide group is especially important for anchoring these analogues in a deep hydrophilic subpocket in the receptor. hA 3 AR homology modeling indicated that 2-aryl and 2-arylethynyl groups have different conformations and receptor environments. The directly connected 2-aryl groups interact with ECL2 of the hA 3 AR, as opposed to the 2-arylethynyl groups, which interact with TM2. Functional assays of selected compounds in G protein-dependent and independent signaling were performed using engineered HEK293T cell lines. In a hA 3 AR miniG α i recruitment assay, 31 (MRS8062) was (slightly) more potent compared to a β-arrestin2 recruitment assay, and its maximal efficacy (E max ) was much higher (165%) than reference nonselective agonist NECA. Thus, in the 2-aryl series, A 3 AR affinity and selectivity were variable and generally reduced compared to the 2-arylethynyl series, with a greater dependence on the specific aryl group present. Selected compounds were protective in an vivo ischemic model of peripheral artery disease (PAD), in which other A 3 AR agonists demonstrated efficacy. Compounds 3a – 3c in the rigidified 2-arylethynyl series significantly decreased the % cell death in this model of skeletal muscle ischemia reperfusion injury/claudication, as previously shown only for moderately A 3 AR-selective ribosides or (N)-methanocarba derivatives (all lacking the 2-arylethynyl group). Thus, we have expanded A 3 AR agonist SAR for (N)-methanocarba adenosines and their application to skeletal muscle ischemia. NIDDK Intramural Res. ZIADK031117

Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Comparative Pharmacophore Modeling of Human Adenosine Receptor A1 and A3 Antagonists

QSAR Analysis of Human Adenosine A3 Receptor Antagonists

2-Substituted -Methanocarba A3 Adenosine Receptor Agonists: In silico, in vitro and in vivo Characterization

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity

2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization

Structure−Activity Relationships of New 1<i>H</i>-Imidazo[4,5-<i>c</i>]quinolin-4-amine Derivatives as Allosteric Enhancers of the A<sub>3</sub>Adenosine Receptor

Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A 3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary

Comparison of the Selectivity of Human Adenosine Receptor Antagonists Based on Structure and Pharmacophore Features

Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Medicinal chemistry of adenosine A3 receptor ligands

Pharmacophore Modeling of Human Adenosine Receptor A2A Antagonists

X-ray Crystallography, DFT Calculations and Molecular Docking of Indole-Arylpiperazine Derivatives As Α1a-Adrenoceptor Antagonists

Structure-Activity Studies of 1 H -Imidazo[4,5- c ]quinolin-4-amine Derivatives as A 3 Adenosine Receptor Positive Allosteric Modulators

Design and synthesis of novel 3-substituted-indole derivatives as selective H3 receptor antagonists and potent free radical scavengers.

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Synthesis of Alkyne Derivatives of a Novel Triazolopyrazine As A2A Adenosine Receptor Antagonists.

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist